Email this article Determination of urinary markers of proteolysis/fibrinolysis and fibroangiogenesis in the kidney in hypertensive patients
- Authors: Nanchikeeva M.L.1, Kozlovskaya L.V.1, Rameev V.V.1, Fomin V.V.1, Bulanov N.M.1, Nanchikeeva ML2, Kozlovskaya LV2, Rameev VV2, Fomin VV2, Bulanov NM2
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University, Moscow
- Issue: Vol 83, No 6 (2011)
- Pages: 23-27
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30844
- ID: 30844
Cite item
Full Text
Abstract
Material and methods. Examination of the kidneys was made in 71 patients with EH degree 1-3. Renal function was assessed by 24-h albuminuria, calculated glomerular filtration rate (GFR) by Cockroft-Golt. Early signs of renal damage were microalbuminuria - MAU (diurnal albuminuria 30-300 mg/day), reduction of GFR ( < 90 ml/min/1.73 m2). EH patients with hypercreatininemia and GFR under 60 ml/min/1.73m2 corresponding to stage III of chronic kidney disease were not included in the study. An additional nephropathy marker was an elevated index of resistance of interlobular renal arteries (RI > 0.65) as shown by dopplerometry. ELISA examined urinary biomarkers of intercellular and cell-matrix interactions in the kidney in EH patients and healthy controls (n = 12).
Results. MAU was detected in 54 (76%) of 71 EH patients, elevated RI > 0.65 - in 37 (52%) patients. Urinary biomarkers of proteolysis/fibrinolysis and fibroangiogenesis were higher in EH patients then in the controls. Urinary excretion of PAI-1, TGF-beta1, VEGF and collagen of type IV in EH patients with MAU was significantly higher than in patients with normoalbuminuria. A strong direct correlation between MAU and the rest above urinary biomarkers was found as well as between urinary excretion of collagen IV and RI. An inverse negative relationship was seen between RI and GFR.
Conclusion. Renal impairment in EH patients is a progressive disorder. Each stage of this process has its own clinicodiagnostic markers. Urinary biomarkers of proteolysis/fibrinolysis and fibroangiogenesis in the kidney are informative for monitoring of early HNP.
About the authors
Mayra Latypovna Nanchikeeva
Email: dom@mbulanov.elcom.ru
Lidiya Vladimirovna Kozlovskaya
Vilen Vilevich Rameev
Email: vvrameev@mtu-net.ru
Viktor Viktorovich Fomin
Email: fomin-vic@mail.ru
Nikolay Mikhaylovich Bulanov
Email: niko-bula@yandex.ru
M L Nanchikeeva
I.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, Moscow
L V Kozlovskaya
I.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, Moscow
V V Rameev
I.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, Moscow
V V Fomin
I.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, Moscow
N M Bulanov
I.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, Moscow
References
- Бикбов Б. Т., Томилина Н. А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2007 гг. (Аналитический отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ 2009; 3: 144-233.
- Amit X., Garg B., Kiberd A. et al. Albuminuria and renal insufficiency prevalence guides population screening; results from the NHANES III. Kidney Int. 2002; 61: 2165-2175.
- Segura J., Campo C., Gil P. et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J. Am. Soc. Nephrol. 2004; 15: 1616-1622.
- Intengan H. D., Schiffrin E. L. Structure and mechanical properties of resistance arteries in hypertension; role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36: 312-318.
- Ochodnicky P., Vettoretti S., Buikema H. et al. Endothelial dysfunction in chronic kidney disease; determinant of susceptibility to end-organ damage and therapeutic response. J. Nephrol 2006; 19 (3): 246-258.
- Rossario R. F., Wesson D. E. Primary hypertension and nephropathy. Curr. Opin. Nephrol. Hypertens. 2006; 15 (2): 130- 134.
- Furumoto T., Fujii S., Nishihara K. et al. Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1). Am. J. Cardiol. 2004; 93 (8): 997-1001.
- Eddy A. A., Fogo A. B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006; 17: 2999-3012.
- Fay W. P., Garg N., Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 1231-1237.
- Inoue M., Oishi C., Shimajiri Y. et al. Clinical usefulness of measurement of urine type IV collagen for detection of early phase of nephropathy in type 2 diabetic patients. Rhinsh. Byori 2008; 56 (7): 564-569.
- Ellis E. D., Forrest K. Y., Erby J. et al. Urinary measurement of transforming growth factor - beta and type IV collagen as knew markers of renal injury: application in diabetic nephropathy. Clin. Chem.1998; 44 (5): 950-956.
- Boutaud A., Borza D.-B., Bondar O. et al. Type IV Collagen of the Glomerular Basement Membrane. J. Biol. Chem. 2000; 275 (39): 30716-30724.
- Бобкова И. Н., Чеботарева Н. В., Рамеев В. В. и др. Роль эндотелиальной дисфункции в прогрессировании хронического гломерулонефрита, современные возможности ее коррекции. Тер. арх. 2005; 6: 92-96.
- Бобкова И. Н., Чеботарева Н. В., Козловская Л. В. и др. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста бета 1 как показатель прогрессирования хронического гломерулонефрита. Тер. арх. 2006; 5: 9-4.
- Комитет экспертов Российского медицинского общества по артериальной гипертензии и Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации. (Третий пересмотр). М.; 2008.
- Нанчикеева М. Л., Козловская Л. В., Буланов М. Н. Возможности ранней диагностики поражения почек у больных гипертонической болезнью. Тер. арх. 2004; 9: 29-34.
Supplementary files
